Posts by Wavemind

“GNUBiotics (Switzerland) has won the Ingredients category in the Startup Innovation Challenge at HiE 2018 in Frankfurt. The company is developing a novel platform for selective microbiota modulation, with an initial market focus on the pet food arena. A subsequent entrance is foreseen into the infant nutrition market.” Read full article

Le Centre de recherche translationnelle en onco-hématologie (CRTOH) a été inauguré lundi 26 novembre 2018 à Genève. Cette structure, réunissant 130 chercheurs et médecins suisses et internationaux, doit jouer un rôle de pont pour intégrer les découvertes de la recherche au traitement des patients.  PLUS D’INFO

“Catalyze4Life, an Innovation Initiative of EPFL has partnered with the similar SPARK program at Stanford University to further advance its mission of fostering innovative research and technologies in the life sciences.” Read full article

Neode devenu Microcity, nomme Caroline Heid comme Présidente Lire l’interview de la nouvelle présidente

“EPFL researchers have developed a hydrogel – made up of nearly 90% water – that naturally adheres to soft tissue like cartilage and the meniscus. If the hydrogel carries repair cells, it could help damaged tissue to heal.” Read full article

“Des chercheurs de l’Université de Genève (UNIGE) ont identifié une molécule appelée tamoxifène, qui peut arrêter la progression de la myopathie myotubulaire, une maladie génétique mortelle. Actuellement, aucun traitement n’existe contre cette déficience génétique.” Lire l’article complet du 20 Minutes

“Thanks to sensors attached to their shoes, long-distance runners can harness the power of algorithms to analyze their stride. The algorithms, developed by EPFL spin-off Gait Up and tested in the Laboratory of Movement Analysis and Measurement (LMAM), are unmatched in terms of precision and the range of parameters measured, such as objective fatigue, cadence,…

“EPFL scientists have discovered how a dysfunction in the immune system can cause an overload of a gut bacterium. The bacterium produces excess lactic acid, which in turn triggers the production of reactive oxygen species that cause damage to cells and many age-related pathologies.” Read complete EPFL article

The Geneva-based startup just announced the completion of its Series B financing round, raising in total CHF 33.2 million. Read Venturelab‘s interview of AMAL Therapeutics‘ CEO and Founder, Madiha Derouazi Link to interview

A yearly international programme for our affiliated companies to increase their visibility. “BioAlps Bridging the World” are events giving you an opportunity to explore new horizons, be showcased with your products and services, to do networking and partnering, be visible while benefiting from BioAlps presence and support. A new way to explore market, improve market…